Peripartum Cardiomyopathy: Recent Insights in its Pathophysiology

Trends in Cardiovascular Medicine

Volumn 18, Issue 5, 2008, Pages 173-179

  Hilfiker Kleiner, Denise ^a   Sliwa, Karen ^b   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CATHEPSIN D; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROLACTIN; STAT3 PROTEIN;

APOPTOSIS; CARDIOMYOPATHY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; HEART PROTECTION; HORMONE SYNTHESIS; HUMAN; INTROSPECTION; KNOCKOUT MOUSE; KNOWLEDGE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK FACTOR;

ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CATHEPSIN D; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; OXIDATIVE STRESS; PARTURITION; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROLACTIN; RISK FACTORS;

EID: 51249113432     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2008.05.002     Document Type: Review

References (50)

1. Brar S.S., Khan S.S., Sandhu G.K., et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 100 (2007) 302-304
2. Cataldo L., Chen N.Y., Yuan Q., et al. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int J Oncol 17 (2000) 1179-1185
3. Cenac A., Djibo A., and Djangnikpo L. Peripartum dilated cardiomyopathy. A model of multifactor disease?. Rev Med Interne 14 (1993) 1033
4. Cole P., Cook F., Plappert T., et al. Longitudinal changes in left ventricular architecture and function in peripartum cardiomyopathy. Am J Cardiol 60 (1987) 871-876
5. Corbacho A.M., Martinez De La Escalera G., and Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173 (2002) 219-238
6. Diwan A., Wansapura J., Syed F.M., et al. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117 (2008) 396-404
7. Eghbali M., Deva R., Alioua A., et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96 (2005) 1208-1216
8. Eghbali M., Wang Y., Toro L., and Stefani E. Heart hypertrophy during pregnancy: a better functioning heart?. Trends Cardiovasc Med 16 (2006) 285-291
9. Elkayam U., Akhter M.W., Singh H., et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111 (2005) 2050-2055
10. Ellis J.E., Ansari A.A., Fett J.D., et al. Inhibition of progenitor dendritic cell maturation by plasma from patients with peripartum cardiomyopathy: role in pregnancy-associated heart disease. Clin Dev Immunol 12 (2005) 265-273
11. Fett J.D. Peripartum cardiomyopathy. Insights from Haiti regarding a disease of unknown etiology. Minn Med 85 (2002) 46-48
12. Fett J.D. Viral infection as a possible trigger for the development of peripartum cardiomyopathy. Int J Gynaecol Obstet 97 (2007) 149-150
13. Fett J.D., Sundstrom B.J., Etta King M., and Ansari A.A. Mother-daughter peripartum cardiomyopathy. Int J Cardiol 86 (2002) 331-332
14. Ge D., Gooljar S.B., Kyriakou T., et al. Association of common JAK2 variants with body fat, insulin sensitivity and lipid profile. Obesity 16 (2008) 492-496
15. Goland S., Schwarz E.R., Siegel R.J., and Czer L.S. Pregnancy-associated spontaneous coronary artery dissection. Am J Obstet Gynecol 197 (2007) e11-e13
16. Gonzalez C., Corbacho A.M., Eiserich J.P., et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 (2004) 5714-5722
17. Harrison R.G. Suppression of lactation. Semin Perinatol 3 (1979) 287-297
18. Hayakawa Y., Chandra M., Miao W., et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation 108 (2003) 3036-3041
19. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16-kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007) 589-600
20. Hilfiker-Kleiner D., Meyer G.P., Schieffer E., et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 50 (2007) 2354-2355
21. Hopp L., Haider B., and Iffy L. Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement. Int J Cardiol 57 (1996) 227-232
22. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
23. Ito N., Eto M., Nakamura E., et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 25 (2007) 2785-2791
24. James A.H., Brancazio L.R., and Ortel T.L. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol 3 (2005) 187-197
25. Kim Y.J., Park H.S., Park M.H., et al. Oxidative stress-related gene polymorphism and the risk of preeclampsia. European Journal of Obstetrics, Gynecology, and Reproductive Biology 119 (2005) 42-46
26. Kothari S.S. Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction?. Int J Cardiol 60 (1997) 111-114
27. Lee S.H., Kunz J., Lin S.H., and Yu-Lee L.Y. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res 67 (2007) 11045-11053
28. Macotela Y., Aguilar M.B., Guzman-Morales J., et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16-kDa prolactin. J Cell Sci 119 (2006) 1790-1800
29. Mayosi B.M. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 93 (2007) 1176-1183
30. Nagafuchi H., Suzuki N., Kaneko A., et al. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 26 (1999) 1890-1900
31. Negoro S., Kunisada K., Fujio Y., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104 (2001) 979-981
32. Patten R.D., Pourati I., Aronovitz M.J., et al. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res 95 (2004) 692-699
33. Patti G., Nasso G., D'Ambrosio A., et al. Myocardial infarction during pregnancy and postpartum: a review. G Ital Cardiol 29 (1999) 333-338
34. Pearson G.D., Veille J.C., Rahimtoola S., et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283 (2000) 1183-1188
35. Reimold S.C., and Rutherford J.D. Peripartum cardiomyopathy. N Engl J Med 344 (2001) 1629-1630
36. Rizeq M.N., Rickenbacher P.R., Fowler M.B., and Billingham M.E. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 74 (1994) 474-477
37. Roberg K., and Ollinger K. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes. Am J Pathol 152 (1998) 1151-1156
38. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47 (2007) 211-242
39. Sliwa K., Fett J., and Elkayam U. Peripartum cardiomyopathy. Lancet 368 (2006) 687-693
40. Sliwa K., Forster O., Libhaber E., et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 27 (2006) 441-446
41. Sliwa K, Forster O, Zhanje F, et al., 2004. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol 93:1441-1443, A10.
42. Sliwa K., Skudicky D., Bergemann A., et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 35 (2000) 701-705
43. Sliwa K., Skudicky D., Candy G., et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4 (2002) 305-309
44. Tabruyn S.P., Sabatel C., Nguyen N.Q., et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via NF-{kappa}B activation. Mol Endocrinol 21 (2007) 1422-1429
45. Tabruyn S.P., Sorlet C.M., Rentier-Delrue F., et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol 17 (2003) 1815-1823
46. Toescu V., Nuttall S.L., Martin U., et al. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf) 57 (2002) 609-613
47. Turkalj I., Braun P., and Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 247 (1982) 1589-1591
48. Van Remmen H., Williams M.D., Guo Z., et al. Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol 281 (2001) H1422-H1432
49. Yokoyama T., Kanda T., Suzuki T., and Murata K. Enhancement of myocardial damage and alteration of lymphocyte subsets in murine model of postpartum myocarditis. Am J Cardiovasc Pathol 4 (1993) 343-351
50. Zhang L., Kao W.H., Berthier-Schaad Y., et al. Haplotype of signal transducer and activator of transcription 3 gene predicts cardiovascular disease in dialysis patients. Journal of the American Society of Nephrology 17 (2006) 2285-2292